{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:32:46Z","timestamp":1777131166905,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jbo.2019.100259","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T12:01:10Z","timestamp":1566475270000},"page":"100259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Atypical femoral fractures from bisphosphonate in cancer patients \u2013 Review"],"prefix":"10.1016","volume":"18","author":[{"given":"Matthew","family":"Lockwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Banderudrappagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2019.100259_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrendo.2015.185","article-title":"The best of both worlds [mdash] managing the cancer, saving the bone","volume":"12","author":"Makhoul","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jbo.2019.100259_bib0002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the united states","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.jbo.2019.100259_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbm4.10024","article-title":"Genetic risk factors for atypical femoral fractures (AFFs): a systematic review","volume":"2","author":"Nguyen","year":"2018","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jbo.2019.100259_bib0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jbo.2019.100259_bib0007","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s00198-017-4169-y","article-title":"Predisposing factors associated with atypical femur fracture among postmenopausal korean women receiving bisphosphonate therapy: 8 years\u2019 experience in a single center","volume":"28","author":"Koh","year":"2017","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.jbo.2019.100259_bib0008","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates","volume":"93","author":"Puhaindran","year":"2011","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.jbo.2019.100259_bib0009","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/jbmr.2818","article-title":"Incidence of atypical femur fractures in cancer patients: The md anderson cancer center experience","volume":"31","author":"Edwards","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0011","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","article-title":"Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis","volume":"24","author":"Ota","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jbo.2019.100259_bib0012","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2019.100259_bib0013","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","article-title":"A case of an unusual subtrochanteric fracture in a patient receiving denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.jbo.2019.100259_bib0014","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr. Osteoporosis Rep."},{"key":"10.1016\/j.jbo.2019.100259_bib0015","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/EJE-17-1002","article-title":"Management of endocrine disease: atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy","volume":"178","author":"Adler","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jbo.2019.100259_bib0016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bone.2016.04.020","article-title":"Strains caused by daily loading might be responsible for delayed healing of an incomplete atypical femoral fracture","volume":"88","author":"Gustafsson","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0017","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.jbo.2019.100259_bib0018","first-page":"7","article-title":"Atypical femoral fractures and current management","volume":"7","author":"Zheng","year":"2016","journal-title":"J. Orthop. Transl."},{"key":"10.1016\/j.jbo.2019.100259_bib0019","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1634\/theoncologist.2018-0218","article-title":"Indirect evaluation of bone saturation with zoledronic acid after long-term dosing","volume":"24","author":"Hortobagyi","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jbo.2019.100259_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bone.2014.06.008","article-title":"The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignment","volume":"66","author":"Saita","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0021","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00774-012-0358-0","article-title":"Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series","volume":"30","author":"Sasaki","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jbo.2019.100259_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00198-007-0533-7","article-title":"Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra","volume":"19","author":"Allen","year":"2008","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.jbo.2019.100259_bib0023","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1138\/20090390","article-title":"Advanced glycation end-products and bone fractures","volume":"6","author":"Vashishth","year":"2009","journal-title":"IBMS BoneKEy"},{"key":"10.1016\/j.jbo.2019.100259_bib0024","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bone.2006.05.013","article-title":"Contribution of the advanced glycation end product pentosidine and of maturation of type i collagen to compressive biomechanical properties of human lumbar vertebrae","volume":"39","author":"Viguet-Carrin","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00198-008-0585-3","article-title":"Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs","volume":"19","author":"Saito","year":"2008","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.jbo.2019.100259_bib0026","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0027","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11914-019-00501-5","article-title":"Mechanisms underlying normal fracture healing and risk factors for delayed healing","volume":"17","author":"Cheng","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2019.100259_bib0029","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/jbmr.3221","article-title":"Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting","volume":"32","author":"LeBlanc","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0030","volume":"2019","year":"2010"},{"key":"10.1016\/j.jbo.2019.100259_bib0031","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/jbmr.3164","article-title":"Screening for atypical femur fractures using extended femur scans by DXA","volume":"32","author":"van de Laarschot","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"1018","key":"10.1016\/j.jbo.2019.100259_bib0032","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1259\/bjr\/99102700","article-title":"Skeletal complications of bisphosphonate use: what the radiologist should know","volume":"85","author":"Haworth","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jbo.2019.100259_bib0033","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0034","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2019.100259_bib0035","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0036","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2019.100259_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.2566","article-title":"Zoledronic acid dosing interval for metastatic cancer\u2014reply","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jbo.2019.100259_bib0038","doi-asserted-by":"crossref","first-page":"183","DOI":"10.11005\/jbm.2015.22.4.183","article-title":"Effect of teriparatide on healing of atypical femoral fractures: a systemic review","volume":"22","author":"Im","year":"2015","journal-title":"J. Bone Metabolism"},{"key":"10.1016\/j.jbo.2019.100259_bib0039","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","article-title":"Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy","volume":"52","author":"Chiang","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100259_bib0040","article-title":"Effect of teriparatide on fracture healing in patients with non\u2010displaced incomplete atypical femur fractures","volume":"27","author":"Cheung","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0041","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2016-2787","article-title":"Scoring system for identifying impending complete fractures in incomplete atypical femoral fractures","volume":"102","author":"Min","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2019.100259_bib0042","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s11999-012-2412-6","article-title":"Bisphosphonate-associated femur fractures have high complication rates with operative fixation","volume":"470","author":"Prasarn","year":"2012","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.jbo.2019.100259_bib0043","first-page":"186","article-title":"The outcome of surgically treated femur fractures associated with long-term bisphosphonate use","volume":"71","author":"Weil","year":"2011","journal-title":"J. Trauma"},{"key":"10.1016\/j.jbo.2019.100259_bib0044","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2019.100259_bib0045","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2019.100259_bib0046","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1056\/NEJMc1612804","article-title":"GGPS1 mutation and atypical femoral fractures with bisphosphonates","volume":"376","author":"Roca-Ayats","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2019.100259_bib0047","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 azure (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2019.100259_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv256","article-title":"Enhanced maf oncogene expression and breast cancer bone metastasis","volume":"107","author":"Pavlovic","year":"2015","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:44Z","timestamp":1761941804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137419301150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":48,"alternative-id":["S2212137419301150"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100259","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical femoral fractures from bisphosphonate in cancer patients \u2013 Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100259"}}